Elizabeth Buchbinder, MD, discusses the implications of the FDA’s decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.
Health Professionals
New Cancer Vaccines on the Horizon: Renewed Hope or Hype?
Vaccines for treating and preventing cancer have long been considered a holy grail in oncology.
Melanoma Density Is Greater in Upper Body Regions Than Lower Body Regions
A significant vertical gradient in cutaneous malignant melanoma density has been identified, as melanoma density is notably higher in upper body regions like the face and ears than in lower body areas. Published in Skin Health and Disease, the study findings highlight the need for targeted sun protection strategies, particularly for high-risk areas frequently exposed to sunlight.
Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma
Panelists discuss how dual immunotherapy for melanoma, including combinations like nivolumab plus ipilimumab or nivolumab plus relatlimab, requires careful consideration of sequencing decisions based on factors such as tumor burden, patient health status, and potential toxicity profiles.